When: Close above $144.90 for 2 sessions AND MACD histogram turning back positive AND RSI holding above 50

Then: Add only on confirmed technical structure, not narrative

HOLD: Trim into $152-$156 exit window; do not add until pullback to 50 SMA near $131 with confirmed MACD reset, or successful retest and hold of $144.90 with expanding volume and MACD histogram expansion.

• PEG of 10.7 is not backward-looking; the market is already paying ten times expected growth rate for a stock at the 96th percentile of its 52-week range
• INTerpath-001 generated a 12.6% single-session move that the market has already priced; detailed Phase 3 data still ahead creates ongoing risk
• mRNA oncology modality demonstrated failure risk with BioNTech Phase 2 colorectal miss; single-partner Moderna concentration is high-risk
• Company deployed $24.6 billion in one quarter on risky assets; GAAP losses in 1Q and 2Q 2026; tangible book value flipped negative; net debt doubled from $18B to $47B in 24 months
• ATR expanded 34% since breakout; MACD histogram compressed 60% in three sessions; 10 EMA pierced intraday to $145.75 from $147.52; three consecutive lower closes from $156.45 high
• 0.21 beta is historical and does not guarantee behavior during hawkish Fed surprise combined with stretched valuations; 50/50 September hike probability repriced 19 percentage points in a week; stock compounded 127% over five years
• Position management requires trimming into strength at $152-$156, not reaching for trades at top of range with patent cliff structural overhang less than two years away

→ vs aggressive: Dismissed PEG of 10.7 and 96th percentile 52-week range as backward-looking anchors, but PEG is forward-looking and percentile placement signals elevated historical valuation risk

→ vs aggressive: Suggested adding on weakness toward $144.90, but this level is only 9% below post-breakout high yet 30% above key moving average support, providing no meaningful margin of safety

→ vs aggressive: Framed $24.6 billion M&A deployment as capital discipline, but it demonstrates pipeline refill desperation ahead of patent cliff with net debt doubling to $47B in 24 months

→ vs aggressive: Treated low 0.21 beta as macro-immune guarantee, but historical beta does not predict behavior during hawkish Fed regime change with 19 percentage point repricing in one week

→ vs aggressive: Read post-breakout pullback as 'healthy breather' confirming bullish thesis, but three consecutive lower closes and MACD compression indicate fading momentum rather than consolidation

HOLD with conditional trim (10-15% max on retest of 152.20 with declining volume and MACD histogram expansion failure), conditional add (25-33% restoration on flush to 144.90 with MACD positive, RSI above 50, and 2-session close above 144.90), and defensive position sizing through September FOMC and detailed data print

• HOLD consensus is correct; valuation is full at 10.7 PEG reflecting 12.6% market re-rating premium already discounted
• Current price at 148.35 after 5.2% pullback from 156.45 over three sessions; ATR expanded 34% in nine sessions; MACD histogram compressed 60% in three sessions
• 10 EMA at 147.52 intraday pierced to 145.75 on the 28th; post-breakout low of 144.90 holding for seven sessions
• RSI at 62 and MACD still positive - trim is premature without technical confirmation of exhaustion
• Trim trigger: retest of 152.20 with declining volume and MACD histogram expansion failure; if 144.90 breaks on heavy volume, that's the trim signal
• Add conditions: daily close above 144.90 for at least two sessions, MACD histogram turning back positive, RSI holding above 50
• MRK has lowest beta in mega-cap pharma at 0.21 - near-bond proxy that holds up well in severe risk-off
• Breakout confirmed on 32.78 million shares; expecting deep retracement to 50 SMA requires multiple negative catalysts not yet materialized
• Detailed INTerpath-001 data print historically produces 5-15% moves in big pharma names - asymmetric upside that systematic trim sacrifices
• Position should be sized at lower end of defensive range through September 16 FOMC and data print, then full sizing restored after both events resolve

→ vs aggressive: Dismissal of valuation is intellectually careless - market already moved 12.6% on news, meaning 10.7 PEG reflects discounted re-rating premium, not backward-looking metric

→ vs aggressive: BioNTech validation argument is double-edged - BNTX failure tells us platform remains hit-or-miss; bull case depends on single partner hitting across multiple tumor types, which is partnership concentration risk

→ vs aggressive: Technical read too charitable - three consecutive lower closes after 34% ATR expansion in nine sessions is compression, not healthy digestion; early buying energy is gone

→ vs conservative: Assuming stock will revisit 131/50 SMA is certainty the data doesn't support - confirmed breakout on 32.78M shares with 144.90 holding for seven sessions; expecting deep retracement requires multiple negative catalysts not yet materialized

→ vs conservative: Trim into 152-156 framework assumes controlled revisit - but at 148.35, getting to 152 requires only 2.5% advance; systematic 20-30% trim sacrifices optionality on detailed data print that historically produces 5-15% moves

→ vs conservative: M&A interpretation states it correctly but weights it as desperation - actual framing is elevated near-term balance sheet risk for long-dated pipeline optionality against 2028 cliff; certainty it's the latter is overstated

→ vs conservative: Beta argument correctly identifies historical nature but overreaches - MRK at 0.21 beta is near-bond proxy within defensive bucket; underperforms in mild risk-off but holds up extremely well in severe risk-off; treating as generic defensive ignores actual defensive mechanics